 |
 |
A021501: Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair. (ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer) EA2142: Randomized [...]
You may have recently heard news regarding changes planned for West Michigan Cancer Center & Institute for Blood Disorders (WMCC). With this article, we hope to clarify the news and explain what patients and caregivers can anticipate moving forward. Our partner hospitals—Borgess and Bronson—have created a plan to strengthen the delivery of cancer care in [...]
Alliance A221101: A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil) to Reduce Cancer-Related Fatigue in Patients with High Grade Glioma. EA1151: Tomosynthesis Mammographic Imaging Screening Trial (TMIST) EAQ162CD: Longitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative Intent PCYC-1134M: informCLL: A Disease Registry for Patients with Chronic Lymphocytic Leukemia S0820: [...]
Dear Patient: As a patient of the West Michigan Cancer Center, Sturgis Hospital Campus (referred to in this letter as “the Sturgis Clinic”), we are writing to inform you that the Sturgis Clinic will be closing on Friday, January 11, 2019. This is part of a reorganization occurring at Sturgis Hospital. You may continue your [...]
A011106: Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study A011502: A Randomized Phase III Double Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for Node-Positive, HER2 Negative Breast Cancer: The Aspirin for Breast Cancer Study (ABC Study) EA1131: A Randomized Phase III Post-Operative [...]
EAY131 (MATCH): Molecular Analysis for Therapy Choice GOG 0238: A randomized trial of pelvic irradiation with or without concurrent weekly cisplatin in patients with pelvic-only recurrence of carcinoma of the uterine corpus GOG 0263: Randomized phase III clinical trial of adjuvant radiation vs. chemoradiation in intermediate risk, stage I/IIA cervical cancer treated with initial radical hysterectomy [...]
EA3132: Phase II Randomized Trial of Adjuvant Radiotherapy with or without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) RTOG 1008: A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A031102: A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors – MALE GENDER ONLY. NRG GU003: A Randomized Phase 3 Trial of Hypofractionated Post-Prostatectomy Radiation Therapy [...]
No Clinical Trials Available
A061402: Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid after Definite Radiation Therapy E1A11: Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic [...]
